|Systematic (IUPAC) name|
|Bioavailability||Not orally absorbed|
|ATC code||J01 QJ51|
|Mol. mass||380.42 g/mol|
|(what is this?)|
Meticillin (INN, BAN) or methicillin (USAN) is a narrow-spectrum β-lactam antibiotic of the penicillin class. It should not be confused with the antibiotic metacycline. In 2005, the name of the drug was changed from methicillin to meticillin in accordance with the International Pharmacopoeia guidelines.
Meticillin was developed by Beecham in 1959. It was previously used to treat infections caused by susceptible Gram-positive bacteria, in particular, penicillinase-producing organisms such as Staphylococcus aureus that would otherwise be resistant to most penicillins, but it is no longer clinically used.[clarification needed]
Its role in therapy has been largely replaced by flucloxacillin and dicloxacillin, but the term meticillin-resistant Staphylococcus aureus (MRSA) continues to be used to describe S. aureus strains resistant to all penicillins.
Meticillin is no longer manufactured because the more stable and similar penicillins such as oxacillin (used for clinical antimicrobial susceptibility testing), flucloxacillin, and dicloxacillin are used medically.
Mode of action
Like other beta-lactam antibiotics, meticillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme (also known as penicillin-binding proteins (PBPs)). These PBPs crosslink glycopeptides (D-alanyl-alanine), forming the peptidoglycan cell wall. Meticillin and other β-lactam antibiotics are structural analogs of D-alanyl-alanine, and the transpeptidase enzymes that bind to them are sometimes called penicillin-binding proteins (PBPs).
Methicillin is actually a penicillinase-resistant B-lactam antibiotic. Penicillinase is a bacterial enzyme produced by bacteria resistant to other B-lactam antibiotics which hydrolyses the antibiotic, rendering it nonfunctional. Methicillin is not bound and hydrolysed by penicillinase, meaning it can kill the bacteria, even if this enzyme is present.
Spectrum of bacterial resistance and susceptibility
At one time, methicillin was used to treat infections caused by certain Gram-positive bacteria including Staphylcoccus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, and Streptococcus pneumoniae. Today, methicillin is not as effective against these organisms due to resistance.
Resistance to methicillin is conferred by activation of a new the activation of a new bacterial PBP gene (mec2). This incodes for the PBP2a. PBP2a works in a similar manner to other PBPs, but it bound by β-lactams with very low affinity, meaning they cannot hydrolyse it and kill the bacteria. Expression of PBPA2 confers resistance to all β-lactams.
These susceptibility data are gtven on a few medically significant bacteria:
- Staphylococcus aureus - 0.125 - >100 μg/ml
- Methicillin resistant Staphylococcus aureus (MRSA) - 15.6 - >1000 μg/ml
- Streptococcus pneumoniae 0.39 μg/ml
Meticillin is insensitive to beta-lactamase (also known as penicillinase) enzymes secreted by many penicillin-resistant bacteria. The presence of the ortho-dimethoxyphenyl group directly attached to the side-chain carbonyl group of the penicillin nucleus facilitates the β-lactamase resistance, since those enzymes are relatively intolerant of side-chain steric hindrance. Thus, it is able to bind to PBPs and inhibit peptidoglycan crosslinking, but it is not bound by or inactivated by β-lactamases.
Meticillin is no longer used to treat patients. Compared to other β-lactamase-resistant penicillins, it is less active, can be administered only parenterally, and has a higher frequency of interstitial nephritis, an otherwise-rare side effect of penicillins. However, it serves a purpose in the laboratory to determine the antibiotic sensitivity of Staphylococcus aureus to other β-lactamase-resistant penicillins.
|Wikinews has related news: Supergerm deaths soar, surpass AIDS in the United States|
- UK parliament MRSA
- Graham Dutfield (30 July 2009). Intellectual property rights and the life science industries: past, present and future. World Scientific. pp. 140–. ISBN 978-981-283-227-6. Retrieved 18 November 2010.
- MRSA—past, present, future
- Gladwin M., Trattler B. Clinical Microbiology made ridiculously simple. 3rd edition. Miami: MedMaster, Inc.; 2004.